Eritrosit dağılım genişliği (RDW), multiple skleroz hastalarında güvenilir bir belirteçtir

Yıl 2024, Cilt: 34 Sayı: 6, 750 - 754, 31.12.2024

Gökhan Özdemir , Fettah Eren , Cihat Özgüncü , Haluk Gümüş

https://doi.org/10.54005/geneltip.1409331

Öz

Amaç: Eritrosit dağılım genişliği (RDW), aktif veya kronik inflamasyonu olan, kardiyovasküler ve diğer otoimmun hastalıkları olan hastalarda prognostik bir belirteçtir. Bu çalışmanın amacı multiple skleroz hastalarında, hastalık alt tiplerinde ve atak gruplarında RDW düzeylerini değerlendirmektir.

Gereç ve Yöntem: Çalışmaya multiple skleroz (MS) hastaları ve sağlıklı bireyler dahil edildi. MS ve kontrol grubunun demografik özellikleri, MS tipleri, MS atağı olup olmadığı ve laboratuvar parametrelerinin analizi değerlendirildi. RDW şu formüle göre hesaplandı: RDW = (RBC Değişkenlik Katsayısı ÷ ortalama MCV) × 100. Tüm gruplar ve alt gruplar RDW değerine göre karşılaştırıldı.

Bulgular: Çalışma, yaş ortalaması 38 (20-64) yıl olan, 74'ü (%70,5) kadın ve 31'i (%29,5) erkek olmak üzere 105 MS hastası üzerinde gerçekleştirildi. MS grubunda RDW değerleri 13,8 (12,1-27,1), kontrol grubunda ise 13,4 (12,1-17,4) idi (p=0,007). ROC analizi, RDW'nin 13,55 kesme noktası kullanıldığında hastalığı %59 duyarlılık ve %54,2 özgüllükle tahmin ettiğini ortaya çıkardı. MS alt grupları ve atak grupları arasında RDW değerine göre istatistiksel olarak anlamlı fark yoktu (p=0,41, p=0,92).

Sonuç: RDW, MS hastalarına yönelik yeni, düşük maliyetli, yaygın olarak ve hemen bulunabilen bir biyobelirteç olabilecektir.

Anahtar Kelimeler

Eritrosit dağılım genişliği, multiple skleroz, biyobelirteç, inflamasyon

Red blood cell distribution width (RDW) is a reliable marker in patients with multiple sclerosis

Öz

Objective: The red blood cell distribution width (RDW) is a prognostic marker in patients with active or chronic inflammation, cardiovascular and the other autoimmune diseases. Our aim of this study is to evaluate levels of the RDW in patients with multiple sclerosis, disease subtypes and attacked groups.

Material and Methods: Multiple sclerosis (MS) patients and healthy individuals were included in the study. Demographic characteristics of MS and control group, types of MS, MS attacks or no attack, and laboratory parameters analysis was evaluated. The RDW was calculated according to the formula: RDW = (Coefficient of Variability of RBC ÷ mean MCV) × 100. All groups and subgroups were compered according to RDW-value.

Results: The study was conducted 105 MS patients, 74 (70.5%) females and 31 (29.5%) males, with a mean age of 38 (20-64) years. RDW values in the MS group were 13.8 (12.1-27.1), whereas in the control group the values were 13.4 (12.1-17.4) (p=0.007). ROC analysis revealed that using a cut-off point of 13.55, RDW predicts MS with a sensitivity of 59% and specificity of 54.2%. There was no statistically significant difference among the MS subgroups and attacked groups according to RDW value (p=0.41, p=0.92).

Conclusion: RDW would be a novel, low cost-effective, widely and immediately available biomarker of patient with MS.

Anahtar Kelimeler

Red blood cell distribution width, multiple sclerosis, biomarker, inflammation

Kaynakça

• 1. Simel DL, DeLong ER, Feussner JR, Weinberg JB, Crawford J. Erythrocyte anisocytosis. Visual inspection of blood films vs automated analysis of red blood cell distribution width. Arch Intern Med 1988; 148:822-824.
• 2. Doğan S, Atakan N. Red Blood Cell Distribution Width is a Reliable Marker of Inflammation in Plaque Psoriasis. Acta Dermatovenerol Croat 2017; 25:26-31.
• 3. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 2009; 133:628-32.
• 4. Guaní-Guerra E, Torres-Murillo B, Muñoz-Corona C, Rodríguez-Jiménez JC, Macías AE, Scavo-Montes DA, et al. Diagnostic Accuracy of the RDW for Predicting Death in COVID-19. Medicina (Kaunas) 2022; 58:613.
• 5. Fava C, Cattazzo F, Hu ZD, Lippi G, Montagnana M. The role of red blood cell distribution width (RDW) in cardiovascular risk assessment: useful or hype? Ann Transl Med 2019; 7:581.
• 6. Yang K, Sun B, Zhang S, Pan Y, Fang J. RDW-SD is Superior to RDW-CV in Reflecting Liver Fibrosis Stage in Patients with Chronic Hepatitis B. Infect Drug Resist 2023; 16:6881-6891.
• 7. Wang RR, He M, Ou XF, Xie XQ, Kang Y. The predictive value of RDW in AKI and mortality in patients with traumatic brain injury. J Clin Lab Anal 2020; 34:e23373.
• 8. Joosse HJ, van Oirschot BA, Kooijmans SAA, Hoefer IE, van Wijk RAH, Huisman A, et al. In-vitro and in-silico evidence for oxidative stress as drivers for RDW. Sci Rep 2023; 13:9223.
• 9. Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci 2017; 7:78.
• 10. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31:752-759.
• 11. Hemond CC, Bakshi R. Magnetic Resonance Imaging in Multiple Sclerosis. Cold Spring Harb Perspect Med 2018; 8:a028969.
• 12. Lunde Larsen LS, Larsson HB, Frederiksen JL. The value of conventional high-field MRI in MS in the light of the McDonald criteria: a literature review. Acta Neurol Scand. 2010; 122:149-158.
• 13. Lo Sasso B, Agnello L, Bivona G, Bellia C, Ciaccio M. Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update. Medicina (Kaunas) 2019; 55:245.
• 14. Kraft GH. Evoked potentials in multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24:717-720.
• 15. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162-173.
• 16. de Gonzalo-Calvo D, de Luxán-Delgado B, Rodríguez-González S, García-Macia M, Suárez FM, Solano JJ, et al. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. Cytokine 2012; 58:193-198.
• 17. Demirkol S, Balta S, Cakar M, Unlu M, Arslan Z, Kucuk U. Red cell distribution width: a novel inflammatory marker in clinical practice. Cardiol J 2013; 20:209.
• 18. Arbel Y, Weitzman D, Raz R, Steinvil A, Zeltser D, Berliner S, et al. Red blood cell distribution width and the risk of cardiovascular morbidity and all-cause mortality. A population-based study. Thromb Haemost 2014; 111:300-307.
• 19. Ljubisavljevic S, Stojanovic I, Cvetkovic T, Vojinovic S, Stojanov D, Stojanovic D, et al. Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation. J Neurol Sci 2014; 337:8-13.
• 20. Peng YF, Cao WY, Zhang Q, Chen D, Zhang ZX. Assessment of the Relationship Between Red Cell Distribution Width and Multiple Sclerosis. Medicine (Baltimore) 2015; 94:e1182.
• 21. Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G, Salemis NS. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res 2013; 5:121-126.
• 22. Warwick R, Mediratta N, Shackcloth M, Shaw M, McShane J, Poullis M. Preoperative red cell distribution width in patients undergoing pulmonary resections for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 45:108-113.
• 23. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One 2013; 8:e80240.